Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Kelem, Kassahun"'
Autor:
Vijay Bhasker, Reddy, Lakmal, Boteju, Asela, Boteju, Li, Shen, Kelem, Kassahun, Nageshwar, Reddy, Adrian, Sheldon, Sanjeev, Luther, Ke, Hu
Publikováno v:
Drug Metabolism and Disposition. 50:361-373
CPI-613, an inhibitor of pyruvate dehydrogenase (PDH) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f5e14c20d640b763e9021d32a99a15
https://doi.org/10.1124/dmd.121.000726
https://doi.org/10.1124/dmd.121.000726
Autor:
Appavu Chandrasekaran, Shaaban F. ElNaggar, Kelem Kassahun, Gopinath C. Nallani, Zhiwei Liu, Li Shen
Publikováno v:
Toxicology and Applied Pharmacology. 338:65-72
Bifenthrin, a pyrethroid insecticide, undergoes oxidative metabolism leading to the formation of 4'-hydroxy-bifenthrin (4'-OH-BIF) and hydrolysis leading to the formation of TFP acid in rat and human hepatic microsomes. In this study, age-dependent m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69a90a7ff2f5d167ddfeea378b9b1821
https://doi.org/10.1016/j.taap.2017.11.010
https://doi.org/10.1016/j.taap.2017.11.010
Autor:
Christine Brandquist, S. Aubrey Stoch, Rose Witter, Cynthia Dempsey, Christopher R. Gibson, Filippos Kesisoglou, Stefan Zajic, Marc L. Reitman, Jeanine E. Ballard, Daria Stypinski, Kelem Kassahun, Anish Mehta
Publikováno v:
The Journal of Clinical Pharmacology. 57:110-117
This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e300cabf64e7659f28ba32a7feefb6ea
https://doi.org/10.1002/jcph.780
https://doi.org/10.1002/jcph.780
Autor:
S Aubrey, Stoch, Jeanine, Ballard, Christopher, Gibson, Filippos, Kesisoglou, Rose, Witter, Kelem, Kassahun, Stefan, Zajic, Anish, Mehta, Christine, Brandquist, Cynthia, Dempsey, Daria, Stypinski, Marc L, Reitman
Publikováno v:
Journal of clinical pharmacology. 57(1)
This open-label 2-period study assessed the effect of multiple-dose administration of rifampin, a strong cytochrome P450 3A (CYP3A) and P-glycoprotein inducer, on the pharmacokinetics of odanacatib, a cathepsin K inhibitor. In period 1, 12 healthy ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a0c501d98dd862901e63a1275a9600c8
https://pubmed.ncbi.nlm.nih.gov/27321774
https://pubmed.ncbi.nlm.nih.gov/27321774
Autor:
Roy Eisenhandler, Diana M. Brainard, Marian Iwamoto, John A. Wagner, Julie A. Stone, Niresh Hariparsad, Alisha Norcross, Chengcheng Liu, Jared Lunceford, Amelia S. Petry, Larissa Wenning, Kelem Kassahun, Emanuel P. DeNoia
Publikováno v:
The Journal of Clinical Pharmacology. 51:943-950
Raltegravir is an HIV-1 integrase strand transfer inhibitor with potent activity against HIV-1. A prior investigation of raltegravir coadministered with rifampin demonstrated a decrease in plasma concentrations of raltegravir likely secondary to indu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6670a3b2be161d29f0335edbcc2dae4
https://doi.org/10.1177/0091270010375959
https://doi.org/10.1177/0091270010375959
Autor:
Julie A. Stone, Eric Mangin, Alisha Rhoton, Keith Gottesdiener, Kalyan Ghosh, William D. Hanley, John A. Wagner, Matthew D. Troyer, Kelem Kassahun, Amelia S. Petry, Marian Iwamoto, Emanuel P. DeNoia, Ping Lu, Larissa Wenning
Publikováno v:
The Journal of Clinical Pharmacology. 48:209-214
Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba459a8708ac091f233084d16b0db2f
https://doi.org/10.1177/0091270007310382
https://doi.org/10.1177/0091270007310382
Autor:
W. Bart Emary, Gary E. Adamson, Rena Zhang, Jamie J. Zhao, Kelem Kassahun, Yuexia Liang, Emily D Adarayan
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 41:1293-1298
Quantitation of geometric isomers of a phosphodiesterase inhibitor was required to determine the extent of interconversion following dosing of a single isomer in preclinical pharmacokinetic studies. Assays were developed for the simultaneous determin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5944424e060749cd4599ba27683cedc5
https://doi.org/10.1016/j.jpba.2006.02.016
https://doi.org/10.1016/j.jpba.2006.02.016
Autor:
Kelly Hamilton, Michael J. Bogusky, Robert B. Lobell, Lorena S. Beese, Joel R. Huff, Samuel L. Graham, Marc Abrams, Jackson B. Gibbs, Christine Fernandes, Ronald G. Robinson, J. Christopher Culberson, Carl F. Homnick, Eileen S. Walsh, Joseph J. Lynch, David C. Heimbrook, Michelle Ellis-Hutchings, Douglas C. Beshore, Hans E. Huber, Kenneth S. Koblan, Jeffrey S. Taylor, George D. Hartman, Hema Bhimnathwala, Kelem Kassahun, Nancy E. Kohl, Theresa M. Williams, Carolyn A. Buser, A. David Rodrigues, Joseph P. Davide, C. Blair Zartman, Steven N. Gallicchio, Ian M. Bell
Publikováno v:
Journal of Medicinal Chemistry. 45:2388-2409
A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4654ba1a8f496a6a73493cd839fe1d14
https://doi.org/10.1021/jm010531d
https://doi.org/10.1021/jm010531d
Autor:
Kelem Kassahun, Anish Mehta, Christopher R. Gibson, Kate Mostoller, David Hreniuk, Chengcheng Liu, Raymond Evers, Stefan Zajic, Chantal Mahon, Denise Morris, Eugene E. Marcantonio, Jairam Palamanda, Cuyue Tang, S. Aubrey Stoch, Jeanine E. Ballard, John A. Wagner
Publikováno v:
Journal of clinical pharmacology. 54(11)
We evaluated the effect of prednisone on midazolam and odanacatib pharmacokinetics. In this open-label, 2-period crossover study in healthy male subjects, midazolam 2 mg was administered (Day -1) followed by odanacatib 50 mg (Day 1) during Part 1. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f068493b9bf03695f523576782930c8d
https://pubmed.ncbi.nlm.nih.gov/24895078
https://pubmed.ncbi.nlm.nih.gov/24895078
Autor:
Kelem Kassahun, Ian McIntosh, Stefan Zajic, Jennifer Talaty, S. Aubrey Stoch, Kenneth A. Koeplinger, Deborah L. Miller, Li Sun, Russell Dixon
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 42(5)
Odanacatib is a selective inhibitor of the cathepsin K enzyme that is expressed in osteoclasts involved in the degradation of bone organic matrix, and is being developed as a novel treatment of osteoporosis. Odanacatib has demonstrated increases in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e200060aaebb8b2a81a70c2d192154b0
https://pubmed.ncbi.nlm.nih.gov/24553380
https://pubmed.ncbi.nlm.nih.gov/24553380